Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.
ECDC assessed the risk to the EU/EEA of the presence and the possible transmission of prions, which have been linked to Creutzfeldt-Jakob disease, by blood and plasma-derived medicinal products (PDMPs) manufactured from donations obtained in the UK.
This technical report assesses the risk of Ebola virus transmission through substances of human origin and offers guidelines on the safety of donations where the potential donors are travellers returning from Ebola-affected countries, people exposed to Ebola virus or patients who have recovered from the disease.
Two developments in the field of variant Creutzfeldt–Jakob disease (vCJD) occurred in 2009. In order to address a number of questions that were raised, ECDC internal and external experts prepared this risk assessment. The document focuses on how these new facts affect the current assumptions regarding transmissibility of the disease through blood transfusion and tissue/cells transplantation.